Open House Biologics Discount Agreements 2026–2028 – Hepatitis B Immunoglobulin (ATC code J06BB04)

Summary

The tender concerns the supply of hepatitis B immunoglobulin (ATC code J06BB04) and the conclusion of a discount agreement for this active substance. TK intends to conclude agreements with all suitable pharmaceutical companies. This is an open-house procedure in which individual negotiations on the contract terms are not conducted and uniform conditions apply to all partners. No exclusivity is guaranteed to any contracting partner. The maximum contract term is 24 months from 1 November 2026, and the contract ends no later than 31 October 2028; if the patent or market exclusivity expires earlier, the contract ends automatically at the end of that month. The precise participation, qualification, compliance and technical requirements must be checked in the official tender documents.